XORTX Announces Submission of Orphan Drug Designation Request for XRx-008 Program to Treat Autosomal Dominant Kidney Disease

Stock Information for XORTX Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About XORTX Therapeutics Inc.

XORTX Announces Publication of Key Research in ADPKD
XORTX Welcomes New Member to the Board of Directors
XORTX Announces Participation in Spring 2024 Investor Conferences
XORTX Announces New Clinical Advisory Board Member
XORTX Highlights Achievements of 2023 and Preparation for Registration Clinical Trial
XORTX Reprices Warrants Issued in Connection with Previous Private Placements
XORTX Finalizes $2.7 Million Prospectus Supplement and Concurrent Private Placement for the Offering of Units
XORTX Raises $2.5 Million Under Prospectus Supplement and Concurrent Private Placement for the Offering of Units

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.